- 2-drug fixed-dose combination (dolutegravir [DTG]+lamivudine [3TC]) is noninferior to a 3- or 4-drug tenofovir alafenamide (TAF)-based regimen through 48 weeks in HIV-infected, virologically suppressed adults with no prior virologic failures or known resistance mutations.
Why this matters
- DTG/3TC can be considered an effective switch option for virologically suppressed, HIV-infected patients.
- Familiarity with European AIDS Clinical Society switch strategies guidelines is recommended.
- 743 participants; 371 switched to DTG/3TC.
- Week 48:
- 0.3% (1) DTG/3TC vs 0.5% (2) TAF had HIV-1 RNA ≥50 copies/mL.
- Per-protocol population: 0 DTG/3TC vs 0.6% TAF had HIV-1 RNA ≥50 copies/mL.
- Adjusted treatment difference (aTD): −0.6 (95% CI, −1.3 to 0.2).
- 93.2% (344) DTG/3TC vs 93.0% (346) TAF had HIV-1 RNA
- aTD: 0.2 (95% CI, −3.4 to 3.9).
- 0 DTG/3TC vs 1 TAF met confirmed virologic withdrawal criteria.
- Week 48 analysis of DTG/3TC switch strategy in HIV-infected, virologically suppressed adults enrolled in an open-label, multicenter, phase 3 noninferiority trial (TANGO).
- Funding: ViiV Healthcare.
- Limited generalizability.
- Withdrawal bias.